Piramal Enterprises’ business unit -- Piramal Critical Care has launched MITIGO (Morphine Sulfate Injection, USP - Preservative-free) in 10 mg/mL and 25 mg/mL concentrations in the US market. Piramal Critical Care will continue to work with wholesalers, hospitals, interventional pain doctors, and pain management centers across the country to ensure availability of MITIGO for patients with intractable chronic pain.
MITIGO is an opioid agonist, for use in continuous microinfusion devices indicated only for intrathecal or epidural infusion for the management of intractable chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Available in 200 mg/20 mL (10 mg/mL) and 500 mg/20 mL (25 mg/mL) preservative-free amber glass vials.
Piramal Enterprises is one of India’s large diversified companies, with a presence in Pharmaceuticals, Healthcare Information Management and Financial Services.
